Sign in

    Neena Bitritto-Garg

    Vice President and Senior Equity Research Analyst at Deutsche Bank

    Neena Bitritto-Garg is a Vice President and Senior Equity Research Analyst at Deutsche Bank, specializing in the biotechnology sector with deep expertise in central nervous system and neurodegenerative disease therapeutics. She covers companies such as Kymera Therapeutics and a portfolio totalling 29 biotech stocks, maintaining a performance record of a 41% success rate and an average return of +3.1% per rating according to TipRanks. Bitritto-Garg began her analyst career at Baird in 2015, later moving to Eisai in 2018, then to JPMorgan in 2019, before joining Deutsche Bank where she launched coverage and has been recognized for bold, accurate investment calls. She is registered with FINRA and holds relevant securities licenses, underpinning her research credentials and regulatory compliance.

    Neena Bitritto-Garg's questions to PROTHENA CORP PUBLIC LTD (PRTA) leadership

    Neena Bitritto-Garg's questions to PROTHENA CORP PUBLIC LTD (PRTA) leadership • Q4 2023

    Question

    Asked for more detail on the ARIA rates across different patient cohorts (APOE4 status) and the rationale for selecting the higher dose levels (200mg, 400mg) and the expected activity differences.

    Answer

    The data shared so far is from the 70mg monthly cohort (Cohort A), which showed encouraging amyloid reduction and ARIA rates consistent with placebo. The additional cohorts remain blinded. The dose levels were selected to fully explore the dose-response relationship up to 400mg, which is the purpose of a Phase 1 study.

    Ask Fintool Equity Research AI

    Neena Bitritto-Garg's questions to Passage BIO (PASG) leadership

    Neena Bitritto-Garg's questions to Passage BIO (PASG) leadership • Q3 2022

    Question

    Neena Bitritto-Garg from Citi sought clarification on the PBFT02 program for FTD, asking if patients currently in the enrollment process are likely to meet screening criteria and be dosed, in order to gauge the timing for data release in 2023.

    Answer

    Chief Medical Officer Mark Forman responded that patient identification efforts have yielded a robust funnel of individuals with FTD and granulin gene mutations. He confirmed these patients are being evaluated for trial suitability and that more information will be shared once a cohort of data becomes available.

    Ask Fintool Equity Research AI

    Neena Bitritto-Garg's questions to Passage BIO (PASG) leadership • Q2 2022

    Question

    Neena Bitritto-Garg from Citi asked for an update on the safety events observed in the first patient dosed in the PBKR03 (Krabbe) trial and inquired if additional patients have been dosed. She also questioned what the primary gating factor is for dosing the first patient in the PBFT02 (FTD) trial.

    Answer

    Interim CEO Edgar Cale stated that for the FTD program, the company expects to dose the first patient shortly due to successful patient identification activities. Chief Medical Officer Mark Forman addressed the Krabbe program, explaining that the first patient's adverse event of acute hydrocephalus has resolved. He confirmed the protocol was updated with additional safety monitoring and that while recruitment is active, no further patients have been dosed to date.

    Ask Fintool Equity Research AI

    Neena Bitritto-Garg's questions to Passage BIO (PASG) leadership • Q1 2022

    Question

    Neena Bitritto-Garg from Citi inquired about the PBFT02 program for frontotemporal dementia (FTD), asking if the company was considering broadening inclusion criteria to speed up enrollment. She also asked for feedback from investigators regarding patient allocation between Passage Bio's study and other competing clinical trials.

    Answer

    Bruce Goldsmith, President and CEO, responded that the inclusion criteria for the FTD trial were indeed broadened late last year to help with enrollment. He explained that the primary challenge is not competition from other studies but the low number of pre-genotyped patients. He detailed company efforts to improve patient identification, such as providing free genetic testing kits to clinical sites, and clarified that the issue is a lack of identified patients to screen, rather than a high rate of screen failures.

    Ask Fintool Equity Research AI

    Neena Bitritto-Garg's questions to ATAI Life Sciences (ATAI) leadership

    Neena Bitritto-Garg's questions to ATAI Life Sciences (ATAI) leadership • Q4 2021

    Question

    Neena Bitritto-Garg from Citi Investment Research asked about the FDA's perspective on studying PCN-101 in an at-home setting and what data on dissociative effects would be required. She also inquired about the differentiation and formulation of the VLS-01 (DMT) program.

    Answer

    CEO Florian Brand clarified that the FDA's decision on at-home use for PCN-101 will be a review issue contingent on clinical data, emphasizing the therapeutic index and the use of a subcutaneous formulation with controlled-administration devices. For VLS-01, he described the development of an oral transmucosal film with IntelGenx, designed for a rapid onset (5-10 minute Tmax) and a 45-minute effect duration to align with the S-ketamine treatment model.

    Ask Fintool Equity Research AI